

amantadine extended-release capsule (GOCOVRI)

Diagnosis Considered for Coverage:

- Dyskinesia associated with Parkinson's disease patient receiving levodopa therapy
- As adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes

Coverage Criteria:

For dyskinesia associated with Parkinson's disease patient receiving levodopa therapy:

- Patient is currently taking immediate-release amantadine **and**
- Medical rationale why Osmolex ER cannot be used, **and**
- Dose does not exceed FDA label maximum.

For adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes:

- Dose does not exceed FDA label maximum, **and**
- Patient has an inadequate response, intolerance, or contraindication to TWO medications from the following:
 - Dopamine agonists (e.g. pramipexole, ropinirole, bromocriptine), or
 - COMT inhibitors (e.g. entacapone, tolcapone), or
 - MAO-B inhibitors (e.g. rasagiline, selegiline)

Coverage Duration: one year

Effective Date: 11/30/2022